Clinical Trial Update: Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers [Phase 2]

View source ↗

Summary

A Phase 2 study to evaluate HT-4253 for preventing Alzheimer's disease in APOE4 carriers, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• HT-4253

Snippet

Sponsor: Halia Therapeutics, Inc. | Conditions: Alzheimers Disease | Phase 2 | Status: NOT_YET_RECRUITING